Why Tenet Healthcare Corporation (THC) stock moved
Tenet Healthcare Corporation (THC) shares rose 0.9% to $205.65 as of July 6, 2026, a slight gain from the prior close of $203.72. BestStocks flagged the session as a major change for THC. Below, we break down what changed for THC, why it matters for investors, how the stock reacted, and the catalysts on the calendar.
THC climbed 0.9% to $205.65
THC rose 8.71% to $207.85 intraday, building on a +2.2% prior-day gain. The move follows reporting on strong first-quarter results and USPI (United Surgical Partners International) expansion, with new ASC (ambulatory surgery center) investments positioning the outpatient segment as a growth driver. Next quarterly earnings release and updates on ASC investment pipeline execution.
What it means for Tenet Healthcare Corporation investors
For Tenet Healthcare Corporation investors, the recent signals are mixed, leaving the near-term picture neutral / mixed. On the constructive side: Positive 0.9% session move; Positive price momentum. Weighing against that: New SEC filing — review for material disclosures. Wall Street's consensus price target sits at $259.50, implying +26.2% upside from $205.65. BestStocks rates the overall signal quality weak (0/100). With earnings roughly 18 days out, the next report is the most likely near-term test of the move.
THC price reaction
THC last traded at $205.65, up $1.93 (+0.95%) from the previous close of $203.72. The session traded on 0.3× average volume (below avg), so participation was unremarkable. Over the past month the stock has ranged between $162.06 and $205.65, and it currently sits about 100% of the way up that band.
Bullish and bearish analyst opinions on Tenet Healthcare Corporation (THC)
The consensus analyst price target on Tenet Healthcare Corporation (THC) is $259.50, 26.2% above the recent $205.65. Over the past 90 days analysts logged 0 upgrades, 8 maintains, and 0 downgrades. Here is how the bullish and bearish cases on THC line up.
The bullish case
- Wall Street's consensus price target of $259.50 implies +26.2% upside from $205.65.
- The Street's most bullish target is $288.00 (+40.0%).
- Positive 0.9% session move.
- Positive price momentum.
The bearish case
- The bearish case is comparatively thin on recent signals; the main risk is that the climb toward the $259.50 consensus target has to be earned, and any of the risks BestStocks tracks could weigh on the shares.
Weighing both sides, BestStocks' composite read of recent signals is roughly balanced, as the bull-versus-bear meter above shows. This is an educational summary of the bull and bear case, not investment advice.
Analyst price targets and ratings are FMP consensus figures as of Jul 6, 2026; other aggregators may differ. High and low targets show the range of estimates, not forecasts.
Previous notable changes for THC
Frequently asked questions about THC
Why did Tenet Healthcare Corporation (THC) stock move?
THC rose 0.9% to $205.65. The move is tied to the catalyst and context summarized above, not unexplained technical trading.
How much did THC stock rise?
THC gained 0.95% ($1.93) versus the prior close of $203.72, last trading at $205.65 on 0.3× average volume.
When is Tenet Healthcare Corporation's next earnings date?
THC's next earnings report is estimated for 2026-07-24 — about 18 days away.
What is the analyst price target for THC?
The consensus analyst price target for THC is $259.50, about 26.2% above the current $205.65. Over the past 90 days, analysts recorded 0 upgrades, 8 maintains, and 0 downgrades.
How BestStocks tracks THC
This page is generated automatically by BestStocks' change-detection system after its price and volume cleared THC-specific materiality thresholds, triggering an evidence check. It draws on 5 tracked change events for THC, cross-checked against the data sources listed below. Price, volume, and market-capitalization figures are the live intraday quote as of July 6, 2026 and refresh as new information is detected; for companies with multiple share classes, market-cap figures can differ by data source. Analyst price targets and ratings are FMP consensus. This is an educational summary of what changed and why — not personalized investment advice.